Related Experiment Video
Updated: May 12, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY
Latania Y Booker1, Titilope A Ishola, Kanika A Bowen
1Department of Surgery The University of Texas Medical Branch Galveston, TX 77555.
Current Pediatric Reviews
|April 23, 2013
Summary
Neuroblastoma immunotherapy shows promise for treating this common pediatric cancer, offering a potentially safer alternative or addition to current treatments with fewer side effects.
Area of Science:
- Pediatric Oncology
- Immunology
- Cancer Therapeutics
Background:
- Neuroblastoma is a significant cause of pediatric cancer deaths in the US.
- Current multimodal therapies have limitations, with poor outcomes for some patients.
- There is a critical need for innovative and more effective neuroblastoma treatments.
Purpose of the Study:
- To review current and emerging immunotherapeutic strategies for neuroblastoma.
- To highlight the potential of immunotherapy as a safer treatment option.
Main Methods:
- Review of existing research on neuroblastoma immunotherapy.
- Identification of various immunotherapeutic approaches under investigation.
Main Results:
- Several immunotherapeutic strategies are being explored, including GD2-targeting antibodies, cytokine therapy, immunocytokines, radioimmunotherapy, and dendritic cell vaccines.
- Immunotherapy presents a potential alternative or adjunct to conventional treatments.
Conclusions:
- Immunotherapy offers a promising avenue for improving neuroblastoma treatment outcomes.
- This approach may provide a safer therapeutic option with reduced adverse effects compared to traditional methods.
